63 results about "Polymeric scaffold" patented technology

A medical device-includes a polymer scaffold crimped to a catheter having an expansion balloon. The scaffold is crimped to the balloon by a process that includes inflating the delivery balloon during a diameter reduction to improve scaffold retention. A crimping temperature is maintained at about the onset of glass transition of the polymer material to facilitate more rapid stabilization of mechanical properties in the scaffold following crimping.

Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery.

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Controlled biodegradable smart responsive scaffold (SRS) materials enhance attachment and viability of cells, i.e. actively guiding their expansion, proliferation and in some cases differentiation, while increasing their biomechanical functionality is an important key issue for tissue regeneration. Chemically build-in functionality in these biodegradable SRS materials is achieved by varying structural functionalization with biocompatible liquid crystal motifs and general polymer composition allowing for regulation and alteration of tensile strength, surface ordering, bioadhesion and biodegradability, bulk liquid crystal phase behavior, porosity, and cell response to external stimuli. Liquid crystal modification of such polymeric scaffolds is an ideal tool to induce macroscopic ordering events through external stimuli. None of these approaches have been demonstrated in prior art, and the use of biocompatible scaffolds that respond to a variety of external stimuli resulting in a macroscopic ordering event is a novel aspect of the present invention.